Topcon backs MistGo Digital to modernize drug delivery and adherence
EYE-GO, a medical technology company based in Denmark, has announced a strategic investment from Topcon Healthcare to accelerate the development of MistGo® Digital, an ophthalmic drug delivery and microdosing device with an integrated adherence monitoring platform. The partnership brings MistGo® into Topcon’s connected care portfolio, with plans to integrate adherence data into existing clinical workflows.
When big pharma meets smart tech
What happens when a next-gen microdosing device meets a diagnostics giant with a knack for connected care ecosystems? You get a partnership that’s more than just another press release, it’s ophthalmology entering its smart tech era in earnest.
On May 16, 2025, EYE-GO, a Copenhagen-based medical technology company, announced a strategic investment from Topcon Healthcare, headquartered in San Diego. The agreement brings EYE-GO’s MistGo® Digital platform, an ophthalmic microdosing device with built-in adherence tracking, into the broader Topcon sphere.
The goal is to address one of the most persistent challenges in chronic eye care: the gap between prescribed treatment and actual use. MistGo® Digital delivers targeted microdoses while recording real-world usage through an integrated digital interface. That data will feed directly into Topcon’s Harmony® platform, putting adherence data alongside imaging and diagnostics for a more complete clinical picture.
READ MORE: WeChat-Based Reminders Double Follow-Up in Pediatric Eye Surgery Trial
Leadership from both sides has also joined forces at the board level, with Topcon Healthcare CEO Ali Tafreshi and ophthalmologist Dr. Robert N. Weinreb now serving on EYE-GO’s board of directors. If successful, the model could give physicians more than a snapshot of disease progression, it could show whether therapy is reaching the eye at all, and whether it’s being followed correctly.
What MistGo® Digital brings to digital adherence monitoring
MistGo® Digital is designed to tackle one of the most stubborn issues in ophthalmology: digital adherence monitoring and medication non-adherence. The handheld device combines microdosed drug delivery with a digital tracking system that logs each administration, verifies usage and sends real-time data to the clinic.
Patients receive reminders and feedback through the platform, while clinicians gain visibility into whether prescribed treatments are being followed as intended. Caregivers can also access usage data, adding another layer of oversight.
In a user preference study comparing MistGo® with standard eye drop bottles, 20 out of 22 participants favored the digital format, citing ease of use and improved confidence in dose delivery.
READ MORE: From Research to Reality: The Corneal Innovations at APAO 2025 Poised to Transform Ophthalmology
According to EYE-GO CEO Henrik Nagel, the technology is “a breakthrough in ophthalmic therapy—bridging the gap between prescription and practice.” For physicians, this added layer of insight could help distinguish between true treatment failure and poor compliance, which can be an often-murky distinction in chronic disease management.
A digital fit with Topcon
By integrating MistGo® Digital into Topcon’s Harmony® platform, the two companies aim to link adherence data directly with imaging, diagnostics and patient history, putting practical use side by side with clinical outcomes. This combined view could support earlier interventions and guide more individualized treatment plans.
“Digital technology is transforming eye care, and MistGo® Digital represents a leap forward in how therapies are delivered and monitored,” said Topcon Healthcare CEO Ali Tafreshi. “EYE-GO’s innovation perfectly complements our vision of connected care pathways.”
The collaboration is a sign that both companies are thinking beyond short-term partnership. Mr. Tafreshi and Dr. Robert N. Weinreb, director of the Hamilton Glaucoma Center at the University of California, San Diego, have both joined EYE-GO’s board of directors. Their involvement shows Topcon is looking to play a long game in tying therapies and diagnostics together.
“In Topcon, we’ve found not only a leading force in eyecare technology but also a visionary partner in the digital health space,” said Christian Stig Møller, Chairman of EYE-GO.
Together, the companies are taking a step toward integrating the full picture—what’s prescribed, what’s happening in the eye and whether the two line up.
Key takeaways
- MistGo® Digital delivers microdosed therapy with built-in adherence tracking
- Real-time usage data can be shared with clinicians and caregivers
- Platform will integrate with Topcon’s Harmony® digital health system
- In user testing, 20 of 22 participants preferred MistGo® to traditional drop bottles
Why adherence still matters
Even with new treatment options on the market, adherence remains one of the most significant and least visible barriers to effective management of chronic eye disease. For conditions like glaucoma, where progression often occurs without symptoms, glaucoma medication compliance becomes crucial, asnon-compliance can quietly undermine even the best-designed therapies.
READ MORE: Implanting Hope and Molecular Mysteries: New Solutions in Glaucoma Treatment
The EYE-GO–Topcon collaboration aims to close that gap. By combining adherence tracking with diagnostic data, the companies are betting on a future where connected care in ophthalmology merges diagnostic insights with real-world medication use. Where treatment plans are built not just on clinical endpoints, but on real-world patient behavior and what’s actually happening between appointments.
Editor’s Note: Read the official announcement from EYE-GO and Topcon for more information.
